文献速递妇科肿瘤

HPV阳性女性p16/Ki-67双染分流后宫颈癌前病变五年风险

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
PubMed 文献 · JAMA Oncol · 2019-01-01

该前瞻性队列研究纳入1549例30岁及以上HPV阳性女性,评估p16/Ki-67双染(DS)分流的长期性能。DS阴性女性5年内≥CIN2和≥CIN3风险均低于阴道镜转诊阈值,3年时超过1年随访阈值。

要点

  • DS阳性者5年≥CIN2风险高于细胞学异常者,分层更优。
  • DS阴性者5年≥CIN2风险低于细胞学正常者。
  • DS阴性女性可安全延长随访间隔至3年。

核心结论

  • p16/Ki-67双染分流在5年内提供优于细胞学的长期风险分层。
  • DS阴性女性宫颈癌前病变风险低,允许安全延长随访间隔至3年。

研究设计与样本

  • 前瞻性队列研究,纳入2012年在Kaiser Permanente Northern California接受常规筛查的1549例30岁及以上HPV阳性女性,随访病历至2017年。

主要发现

  • DS阴性女性5年内≥CIN2和≥CIN3风险均低于阴道镜转诊阈值,3年时超过1年随访阈值。

临床怎么用

  • 对HPV阳性女性可采用p16/Ki-67双染分流,DS阴性者可安全将随访间隔延长至3年。

局限性

  • 研究基于单一医疗系统人群,随访时间中位3.7年,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: As cervical cancer screening transitions to primary human papillomavirus (HPV) testing, effective triage and management of HPV-positive women is critical to avoid unnecessary colposcopy referral and associated harms while maintaining high sensitivity for cervical precancer. Triage with p16/Ki-67 dual-stain (DS) testing has shown high sensitivity and specificity for detection of cervical precancers; however, longitudinal studies are needed to determine the long-term risk of precancer following a negative DS result. OBJECTIVE: To evaluate the longitudinal performance of p16/Ki-67 DS triage for detection of cervical precancer in HPV-positive women over 5 years of follow-up in the context of clinical management thresholds. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of HPV-positive women 30 years or older undergoing routine cervical cancer screening in 2012 with HPV and Papanicolaou (hereinafter "cytology") co-testing within the Kaiser Permanente Northern California health care system. Follow-up of medical records was conducted through 2017. EXPOSURES: All p16/Ki-67 DS testing was performed on residual SurePath material, and slides were evaluated for p16/Ki-67 positivity. MAIN OUTCOMES AND MEASURES: Histological end points were ascertained from the clinical database through 2017. We estimated 5-year cumulative risks of cervical intraepithelial neoplasia grades of 2 or worse (≥CIN2) or grades 3 or worse (≥CIN3) by baseline DS and cytology at yearly intervals using Logistic Weibull models. Risks were compared with clinical management thresholds for colposcopy referral and a 1-year return interval. RESULTS: Among the 1549 HPV-positive women in this study, the mean age at enrollment was 42.2 years, and the median follow-up time was 3.7 years (range, 0.2-5.4 years). Positive DS results were associated with significantly higher cumulative 5-year risks of ≥CIN2 compared with abnormal cytology (31.0%; 95% CI, 27.2%-35.3% vs 25.0%; 95% CI, 21.7%-28.7%; P = .03). Women with DS-negative findings had significantly lower 5-year risks of ≥CIN2 compared with women with normal cytology (8.5%; 95% CI, 6.5%-11.1% vs 12.3%; 95% CI, 9.8%-15.4%; P = .04). In DS-negative women, the risks of both ≥CIN2 and ≥CIN3 remained below the colposcopy referral threshold for all 5 years, crossing the 1-year return threshold at 3 years. CONCLUSIONS AND RELEVANCE: Triage with p16/Ki-67 DS provides better long-term risk stratification than cytology over 5 years. The low risk of cervical precancer in p16/Ki-67 DS-negative women permits safe extension of follow-up intervals for 3 years.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Clarke MA, Cheung LC, Castle PE, et al. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncol. 2019. PMID: 30325982. doi:10.1001/jamaoncol.2018.4270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。